

POST-TEST

Oncology Today with Dr Neil Love: Special Edition — Key Presentations from the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting on Gynecologic Cancers

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. Which of the following measures best represents the objective response rates observed with trastuzumab deruxtecan in patients with gynecologic malignancies in the DESTINY Pan-Tumor02 trial?
 - a. 5-10%
 - b. 25-35%
 - c. 45-60%**
 - d. Greater than 70%
2. Which of the following measures best represents the reduction in the risk of progression or death for patients in the ITT population receiving chemotherapy with bevacizumab/durvalumab/olaparib in the Phase III DUO-O trial?
 - a. 7%
 - b. 17%
 - c. 37%**
 - d. 67%
3. Which of the following any-grade special adverse events is most commonly observed in patients with platinum-resistant ovarian cancer receiving mirvetuximab soravtansine, according to Phase III clinical data?
 - a. Blurred vision**
 - b. Dry mouth
 - c. Insomnia
 - d. Nail changes
4. What was the approximate reduction in the risk of progression or death observed with the addition of durvalumab to chemotherapy for patients with advanced or recurrent mismatch repair-deficient/microsatellite instability-high endometrial cancer?
 - a. 15%
 - b. 30%
 - c. 50%
 - d. 70%**
5. Recent updates from the KEYNOTE-826 trial demonstrated a significant improvement in which of the following outcomes for patients with persistent, recurrent or metastatic cervical cancer?
 - a. Progression-free survival
 - b. Overall survival
 - c. Both A and B**
 - d. Neither A nor B